Researchers reduce stem cell dysfunction and metabolic disease in aged mice
Mayo Clinic researchers have taken what they hope will be the first step toward preventing and reversing age-related stem cell dysfunction and metabolic disease. That includes diabetes, which affects 12.2 million Americans age 60 and older, according to the National Council on Aging. In this study, researchers discovered methods for reducing these conditions in naturally aged mice.
"Our work supports the possibility that by using specific drugs that target senescent cells -- cells that contribute to frailty and disease associated with age -- we could stop human senescent cells from releasing toxic proteins that are contributing to diabetes and breakdowns in stem cells in older individuals," says James Kirkland, M.D., Ph.D., director of the Mayo Clinic Robert and Arlene Kogod Center on Aging and senior author of the study.
Researchers from the Center on Aging found that human senescent fat cells release a protein called activin A that impairs the function of fat tissue stem cells and fat tissue. They discovered an activin A increase in the blood and fat tissue of the aged mice.
Treatment with Janus kinase (JAK) inhibitor drugs in aged mice, equivalent to 80-year-old people, decreased the amounts of activin A and partially reversed the fat tissue insulin resistance that contributes to diabetes in old age. In aged mice that are engineered to express a drug-activated gene in their senescent cells (called INK-ATTAC mice) treatment triggering the gene removed senescent cells, decreased activin A and increased the proteins that promote insulin sensitivity and reduce diabetes. This paralleled effects of the JAK inhibitor in normal, naturally aged mice.
"The treated animals had improved glucose and insulin tolerance tests, tests that indicate the severity of diabetes," Dr. Kirkland says. "Our work suggests that targeting senescent cells or their products could be a promising avenue for delaying, preventing, alleviating or treating age-related stem cell and tissue dysfunction and metabolic disease."
Original publication
Ming Xu, Allyson K Palmer, Husheng Ding, Megan M Weivoda, Tamar Pirtskhalava, Thomas A White, Anna Sepe, Kurt O Johnson, Michael B Stout, Nino Giorgadze, Michael D Jensen, Nathan K LeBrasseur, Tamar Tchkonia, James L Kirkland; "Targeting senescent cells enhances adipogenesis and metabolic function in old age"; eLife; 2015
Original publication
Ming Xu, Allyson K Palmer, Husheng Ding, Megan M Weivoda, Tamar Pirtskhalava, Thomas A White, Anna Sepe, Kurt O Johnson, Michael B Stout, Nino Giorgadze, Michael D Jensen, Nathan K LeBrasseur, Tamar Tchkonia, James L Kirkland; "Targeting senescent cells enhances adipogenesis and metabolic function in old age"; eLife; 2015
Organizations
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.